Pfizer Inc. (PFE)
Pre-market:
| Previous close | 28.66 |
| Open | 28.66 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 4000 |
| Day's range | 28.64 - 29.53 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 41,345,476 |
| Market cap | 166.088B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.68 (5.73%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
- Insider Monkey
Is Pfizer Inc. (NYSE:PFE) the Best Gene Therapy Stock to Buy Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Pfizer Inc. (NYSE:PFE) is the best gene therapy stock to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach has […]
- Zacks
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
